This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Opexa Therapeutics’ Therapy For Multiple Sclerosis Featured In FOX Television News Story

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce that Tcelna has been featured in a FOX Atlanta Channel 5 Newscast titled “New Therapy Could Battle Autoimmune Diseases.” The story by FOX Medical Team reporter Beth Galvin highlights Opexa’s ongoing Phase IIb clinical trial in secondary progressive MS and provides an interview with Dr. Ben Thrower, the Medical Director at the Multiple Sclerosis Institute at Shepherd Center in Atlanta, Georgia, and one of the principal investigators in Opexa's Abili-T clinical trial.

The story can be accessed at and from Opexa’s website.

“Tcelna offers hope to many individuals suffering from MS,” commented Dr. Thrower. “We are currently enrolling patients in the Phase IIb clinical trial at our facility and maintain hope that Tcelna could become a safe and effective alternative for the treatment of MS. The therapy acts to restore the function of the body’s immune system to enable the body to fight the disease directly. Since the therapy uses the patient’s own T-cells, the risk of complication is low. Importantly, Tcelna is being developed for secondary progressive MS, as currently, there are limited treatment options for patients with this form of MS.”

"The MS Institute at Shepherd Center in Atlanta is an important site in our Phase IIb clinical trial,” commented Neil K. Warma, President and Chief Executive Officer of Opexa. “We appreciate the significant effort of Dr. Thrower and his team and their commitment to the MS community. The Abili-T trial is progressing well and we have over 30 sites in the United States and Canada committed to the ongoing enrollment of patients with secondary progressive MS. In addition, we are encouraged with the coverage by FOX News of the potential our T-cell therapy has to effectively treat MS and address a community with a great unmet need, as well as to make a real difference in the lives of the patients."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs